why choose us

First received: September 17, 2024

Clinical Trial: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Breast Cancer
Triple Negative Breast Cancer

Study Type: INTERVENTIONAL


Official Title: Neoadjuvant Phase II Study of Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (The TELESCOPE Study)

Brief Summary: This is a single arm, proof of concept phase II clinical trial to evaluate the combination of Pembrolizumab and Carboplatin plus Paclitaxel in patients with localized TNBC (tumor size ? 10 mm and ? 20 mm by mammogram and/or ultrasound, and/or ? 10 mm and ? 25 mm by breast MRI if performed within 2 weeks after biopsy, considering possible tissue inflammation post-procedure, as per local assessment), node-negative status (by clinical exam and local radiological evaluation) and who have not previously received…

Read more